HOME >> BIOLOGY >> NEWS
DOE begins international effort to sequence tree genome

OAK RIDGE, Tenn., Feb. 4, 2002 -- Cottonwoods, hybrid poplars and aspens could play a role in improving the environment, displacing imported oil and creating domestic jobs, but first scientists from the Department of Energy, Oak Ridge National Laboratory and around the world have to sequence the Populus genome.

Trees like cottonwood, hybrid poplar and aspen have long been used as model organisms in forestry, and the choice of Populus as the first tree genome to sequence is due in large part to their rapid growth rate, small genome size and widespread use in areas of interest to the forest industry and DOE.

"This effort will furnish scientists both in this country and abroad with an unprecedented molecular parts list for a tree," said Jerry Tuskan, a researcher in ORNL's Environmental Sciences Division. "Such a list will provide the scientific community with a catalog of genes, knowledge as to what these genes do in trees and an exciting opportunity to better understand how trees grow."

Ultimately, this information will allow scientists to more effectively use trees to carry out important functions like carbon sequestration and enhanced production of biomass for fuels and fiber.

This project builds upon the success that DOE has had in mapping the human genome, a decade-long effort that is expected to lead to cures and the prevention of diseases in people. While sequencing the human genome took years, researchers at DOEs Joint Genome Institute, ORNL and cooperating institutions expect to make the genetic blueprint of Populus available within 18 months. And they expect the payback to be significant.

"Genetic sequencing of Populus is expected to lead to faster growing trees, trees that produce more biomass for conversion to fuels, while also sequestering carbon from the atmosphere," said Stan Wullschleger of ORNLs Environmental Sciences Division. "In addition, trees with unique traits may be used in phytoremediation, a process
'"/>

Contact: Ron Walli
wallira@ornl.gov
865-576-0226
DOE/Oak Ridge National Laboratory
4-Feb-2002


Page: 1 2 3

Related biology news :

1. New hydrothermal vents discovered as South Pacific Odyssey research begins
2. DCI donor services begins distribution of tissue implants
3. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
4. Work begins on powering a sustainable future for the UK
5. As autumn approaches, this chickadees brain begins to expand
6. New study begins to unravel fate of toxic pollutants harbored in Arctic waters
7. UCSF begins distributing the first of its two embryonic stem cell lines
8. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
9. Nabi Biopharmaceuticals begins human testing of novel vaccine to fight nicotine addiction
10. The pathway to anxiety begins early in life
11. Montana State University begins major trout and salmonid book collection

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: DOE begins international effort sequence tree genome

(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/17/2015)... Houston, TX (PRWEB) April 17, 2015 ... genomics and proteomics technologies, announced today that it ... sequencing system, an innovative multiplex PCR based targeted ... ultra-high resolution sequence analysis, that enables accurate detection ... pending Relay-PCR™ and Omega-Primer™ technologies. The company will ...
(Date:4/16/2015)... 16, 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) ... quarter results on Thursday, April 30, 2015 at 4:00 ... will host a conference call at 4:30 PM Eastern ... company’s outlook for the future. , The conference call ... the homepage and in the Investor Relations section of ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
Breaking Biology Technology:LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: